Janssen Pharmaceutica Nv

University of Washington

Frances Meredith Hocutt

Hariharan Venkatesan

Mark D Rosen

Michael H Rabinowitz

Kyle T Tarantino

Barry Eastman Leonard, Jr

Lucy Xiumin Zhao

Victor K Phuong

Hillary M Peltier

Michael H Gelb

Frantisek Turecek

C Ronald Scott

Zdenek Spacil

Mariana Natali Barcenas Rodriguez

Arun Babu Kumar

Scott D Bembenek

Barry Eastman Leonard

Adenek Spacil

Hiriharan Venkatesan

The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

Benzoimidazoles as prolyl hydroxylase inhibitors

Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.

Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII

Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IV A, MPS-VI, and MPS VII. In one aspect, the invention provides methods for assaying one or more enzymes associated with a lysosomal storage disease. In a first embodiment, the method includes: (a) contacting a sample with a first solution to provide a solution comprising one or more lysosomal enzymes; (b) contacting the one or more lysosomal enzymes in solution with an enzyme substrate for each lysosomal enzyme to be analyzed and incubating the substrates with the enzymes for a time sufficient to provide a solution comprising an enzyme product for each lysosomal enzyme present in the sample.

Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.

Quinazolinones as prolyl hydroxylase inhibitors

The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity. 

Growing community of inventors

Seattle, WA, United States of America

Frances Meredith Hocutt